We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA flagged a Shilpa Medicare facility in Telangana, India for numerous violations including noncompliant labeling, sterility procedures and testing methods. Read More
ClinicalTrials.gov received a new set of usability updates last month, including additional local search functions, a new glossary feature and redesigned study record pages. Read More
The Drug Enforcement Administration proposed listing unscheduled fentanyl products as Schedule I controlled substances to help address the opioid crisis. Read More
A new FDA draft guidance recommends sponsors include new class labeling and prescribing information for combined hormonal contraceptives containing estrogen and progestin. Read More
Kmart agreed to pay a $32.3 million settlement over charges that its in-store pharmacies failed to report discounted drug prices to federal programs and, therefore, were reimbursed at inflated prices. Read More
Six U.S. senators called on the Drug Enforcement Administration to update regulations on partial filling of Schedule II drugs to help address the opioid addiction crisis. Read More